Drug levels, immunogenicity and assessment of active sacroiliitis in patients with axial spondyloarthritis under biologic tapering strategy

被引：8

作者：

Almirall, Miriam ^{[1
]}

Gimeno, Ramon ^{[2
]}

Carlos Salman-Monte, Tarek ^{[1
]}

Iniesta, Silvia ^{[1
]}

Pilar Lisbona, Maria ^{[1
]}

Maymo, Joan ^{[1
]}

机构：

[1] Univ Autonoma Barcelona, Dept Rheumatol, Parc Salut Mar,Passeig Maritim 25-29, Barcelona 08003, Spain

[2] IMIM, Dept Immunol, Barcelona, Spain

来源：

RHEUMATOLOGY INTERNATIONAL | 2016年 / 36卷 / 04期

关键词：

Biologic tapering strategy; Axial spondyloarthritis; Immunogenicity; Active sacroiliitis; ANKYLOSING-SPONDYLITIS; ADALIMUMAB; INFLAMMATION; MULTICENTER; INFLIXIMAB; EFFICACY; SAFETY;

D O I：

10.1007/s00296-016-3428-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The aim of the study was to assess drug levels, immunogenicity and sacroiliitis on MRI in patients with axial spondyloarthritis under biologic tapering strategy. Consecutive patients with axial spondyloarthritis who remained in low disease activity more than 1 year after dose tapering of infliximab and adalimumab were included. Plasma drug concentrations of TNF inhibitors and antidrug antibodies were determined, and MRI of sacroiliac joints was evaluated. Of twenty patients included, eighteen had therapeutic drug levels, no patient had anti -drug antibodies, and no patient had active sacroiliitis on MRI. These data could support the biologic tapering strategy and their maintenance over time.

引用

页码：575 / 578

页数：4

共 16 条

[1]

Arends S, 2010, CLIN EXP RHEUMATOL, V28, P661

[2] Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].

Braun, J ;

Brandt, J ;

Listing, J ;

Zink, A ;

Alten, R ;

Golder, W ;

Gromica-Ihle, E ;

Kellner, H ;

Krause, A ;

Schneider, M ;

Sörensen, H ;

Zeidler, H ;

Thriene, W ;

Sieper, J .

LANCET, 2002, 359 (9313) :1187-1193

[3] Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis [J].

de Vries, M. K. ;

van der Horst-Bruinsma, I. E. ;

Nurmohamed, M. T. ;

Aarden, L. A. ;

Stapel, S. O. ;

Peters, M. J. L. ;

van denderen, J. C. ;

Dijkmans, B. A. C. ;

Wolbink, G. J. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (04) :531-535

[4] Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up [J].

Kneepkens, Eva L. ;

Wei, James Cheng-Chung ;

Nurmohamed, Michael T. ;

Yeo, Kai-Jieh ;

Chen, C. Y. ;

van der Horst-Bruinsma, Irene E. ;

van der Kleij, Desiree ;

Rispens, Theo ;

Wolbink, Gertjan ;

Krieckaert, Charlotte L. M. .

ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (02) :396-401

[5] Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis [J].

Lambert, Robert G. W. ;

Salonen, David ;

Rahman, Proton ;

Inman, Robert D. ;

Wong, Robert L. ;

Einstein, Steven G. ;

Thomson, Glen T. D. ;

Beaulieu, Andre ;

Choquette, Denis ;

Maksymowych, Walter P. .

ARTHRITIS AND RHEUMATISM, 2007, 56 (12) :4005-4014

[6] Low-dose Infliximab (3 mg/kg) Significantly Reduces Spinal Inflammation on Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis: A Randomized Placebo-controlled Study [J].

Maksymowych, Walter P. ;

Salonen, David ;

Inman, Robert D. ;

Rahman, Proton ;

Lambert, Robert G. W. .

JOURNAL OF RHEUMATOLOGY, 2010, 37 (08) :1728-1734

[7] Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease [J].

Navarro-Compan, Victoria ;

Moreira, Virginia ;

Ariza-Ariza, Rafael ;

Hernandez-Cruz, Blanca ;

Vargas-Lebron, Carmen ;

Navarro-Sarabia, Federico .

CLINICAL RHEUMATOLOGY, 2011, 30 (07) :993-996

[8] Dosage Adjustment of Anti-Tumor Necrosis Factor-α Inhibitor in Ankylosing Spondylitis Is Effective in Maintaining Remission in Clinical Practice [J].

Paccou, Julien ;

Bacle-Boutry, Marie-Astrid ;

Solau-Gervais, Elisabeth ;

Bele-Philippe, Peggy ;

Flipo, Rene-Marc .

JOURNAL OF RHEUMATOLOGY, 2012, 39 (07) :1418-1423

[9] Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor α inhibitors [J].

Pedersen, Susanne Juhl ;

Sorensen, Inge Juul ;

Hermann, Kay-Geert A. ;

Madsen, Ole Rintek ;

Tvede, Niels ;

Hansen, Michael Sejer ;

Thamsborg, Gorm ;

Andersen, Lis Smedegaard ;

Majgaard, Ole ;

Loft, Anne Gitte ;

Erlendsson, Jon ;

Asmussen, Karsten ;

Johansen, Julia S. ;

Jurik, Anne Grethe ;

Moller, Jakob ;

Hasselquist, Maria ;

Mikkelsen, Dorrit ;

Skjodt, Thomas ;

Hansen, Annette ;

Ostergaard, Mikkel .

ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (06) :1065-1071

[10] Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity [J].

Plasencia, Chamaida ;

Kneepkens, Eva L. ;

Wolbink, Gertjan ;

Krieckaert, Charlotte L. M. ;

Turk, Samina ;

Navarro-Compan, Victoria ;

L'Ami, Merel ;

Nurmohamed, Mike T. ;

van der Horst-Bruinsma, Irene ;

Jurado, Teresa ;

Diego, Cristina ;

Bonilla, Gema ;

Villalba, Alejandro ;

Peiteado, Diana ;

Nuno, Laura ;

van der Kleij, Desiree ;

Rispens, Theo ;

Martin-Mola, Emilio ;

Balsa, Alejandro ;

Pascual-Salcedo, Dora .

JOURNAL OF RHEUMATOLOGY, 2015, 42 (09) :1638-1646

← 1 2 →